Ulcerative Colitis (UC)NCT07766733
The Safety and Efficacy of Good Feeling Power® for IBD Patients
A study testing Good Feeling Power® in people with Ulcerative Colitis (UC) and Crohn Disease (CD), run by Good Feeling Products GmbH at 1 site in Spain.
Trial summary
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease. Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Ulcerative Colitis (UC), Crohn Disease (CD)
- What is being tested?
- Good Feeling Power®
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteSpain
- Study dates
- 6 Nov 2023to 20 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 18 - 64
- BMI 18.5 - 32.0 kg/m²
- Mild-to-moderate UC or colonic/ileal CD
- At least one prior episode of active disease
Who cannot join
- Extensive colonic resection or subtotal or total colectomy
- Currently required or anticipated surgical intervention during the study
- Any prior exposure to natalizumab, efalizumab, or rituximab
- History or evidence of colonic mucosal dysplasia
- Female patients who are lactating or have a positive pregnancy test
- Any unstable or uncontrolled medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label Pilot Study to Determine Safety and Efficacy of Good Feeling Power® (a Dietary Supplement) in Patients With Either Ulcerative Colitis or Colonic/Ileal Crohn's Disease
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD)
- Being tested
- Good Feeling Power®
- Medical subject headings
- Colitis, Ulcerative, Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Good Feeling Power®Dietary supplement
The dietary supplement Good Feeling Power®, isolated from the fruiting bodies of the tree mushroom (tinder fungus, lat. Fomes fomentarius), was administered orally as a drink.
| Study group | Role | What they receive |
|---|---|---|
| The dietary supplement Good Feeling Power® was administered to all enrolled patients. | Experimental | Not described Receives: Dietary Supplement: Good Feeling Power® |
What is being measured
The primary outcome is the main question the study is designed to answer.
The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters
The primary outcomes are the changes in gastrointestinal symptoms (Simple Clinical Colitis Activity Index for ulcerative colitis (UC) patients and the Harvey-Bradshaw Index for Crohn's disease (CD) patients), biochemical biomarkers in feces (calprotectin, immunoglobulin A, hemoglobin), and endoscopic parameters (Mayo Endoscopic Score).
Measured: From baseline to Day180
Secondary outcomes (1)
Safety of Good Feeling Power® for patients with mild-to-moderate UC or CD
The secondary outcomes are the safety of the tested product, as monitored by vital signs, ECG, physical condition, blood parameters (hematology, clinical chemistry, coagulation, and inflammation), urine analysis, and the absence of the product-related adverse effects.
Measured: From baseline to Day180
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start6 Nov 2023
- Primary completion20 Jun 2025
- Study completion20 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Good Feeling Products GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07766733
- Sponsor's protocol ID
- GFP_IDA14-1
- Status last verified
- Aug 2026
- First submitted
- 6 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label Pilot Study to Determine Safety and Efficacy of Good Feeling Power® (a Dietary Supplement) in Patients With Either Ulcerative Colitis or Colonic/Ileal Crohn's Disease
- ClinicalTrials.gov ID
- NCT07766733
- Acronym / sponsor ID
- GFP_IDA14-1
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Good Feeling Products GmbHIndustry (pharma, biotech, devices)
- Study start
- 6 Nov 2023 (actual)
- Primary completion
- 20 Jun 2025 (actual)
- Study completion
- 20 Jun 2025 (actual)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The dietary supplement Good Feeling Power® was administered to all enrolled patients. | Experimental | Dietary Supplement: Good Feeling Power® |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Adults aged 18 - 64
- BMI 18.5 - 32.0 kg/m²
- Mild-to-moderate UC or colonic/ileal CD
- At least one prior episode of active disease
Key exclusion criteria (6 listed)
- Extensive colonic resection or subtotal or total colectomy
- Currently required or anticipated surgical intervention during the study
- Any prior exposure to natalizumab, efalizumab, or rituximab
- History or evidence of colonic mucosal dysplasia
- Female patients who are lactating or have a positive pregnancy test
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Good Feeling Power®The dietary supplement Good Feeling Power®, isolated from the fruiting bodies of the tree mushroom (tinder fungus, lat. Fomes fomentarius), was administered orally as a drink. | Dietary supplement | The dietary supplement Good Feeling Power® was administered to all enrolled patients. |
Primary outcome
The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters
Time frame: From baseline to Day180
The primary outcomes are the changes in gastrointestinal symptoms (Simple Clinical Colitis Activity Index for ulcerative colitis (UC) patients and the Harvey-Bradshaw Index for Crohn's disease (CD) patients), biochemical biomarkers in feces (calprotectin, immunoglobulin A, hemoglobin), and endoscopic parameters (Mayo Endoscopic Score).
1 secondary outcome
Safety of Good Feeling Power® for patients with mild-to-moderate UC or CD
Time frame: From baseline to Day180
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Ulcerative Colitis (UC)
Recruiting
Multi-omics Dissection of Gut Microbiome Engraftment During FMT
Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC)
Not yet recruiting
Online Pain Education for Crohn's Disease and Ulcerative Colitis
Crohn's Disease, Ulcerative Colitis (UC)
Not yet recruitingEarly Phase 1
Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)
Pouchitis, UC - Ulcerative Colitis
Not yet recruitingObservational study
Validation and Clinical Impact of GLIM Criteria in Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Not yet recruitingPhase 4
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Good Feeling Power® in people with Ulcerative Colitis (UC) and Crohn Disease (CD), run by Good Feeling Products GmbH at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The effect of Good Feeling Power® on gastrointestinal symptoms, biochemical biomarkers and endoscopic parameters (time frame: From baseline to Day180). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026; AzTrials last refreshed its copy on 26 Oct 2026.